CVS Health
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 weeks.
- Recent price momentum is +3.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2852 U.S. stocks StockVane covers.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 24.9x | Better than 35% |
| Forward P/E | 13.7x | Better than 61% |
| Price / Sales | 0.3x | Better than 96% |
| P/E vs own 5-yr range | 69th pctl | Better than 41% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 7.6% | Better than 57% |
| Net income CAGR (3Y) | -25.7% | Better than 13% |
| Free cash flow CAGR (3Y) | -16.6% | Better than 21% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 13.8% | Better than 10% |
| Operating margin | 2.6% | Better than 27% |
| Net margin | 0.4% | Better than 27% |
| Return on equity | 2.3% | Better than 31% |
| Return on invested capital | 2.7% | Better than 36% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -12.3% | Better than 24% |
| 6-month return | 22.0% | Better than 79% |
| 12-month return (ex latest month) | 8.4% | Better than 47% |
| Distance below 52-week high | 13.5% | Better than 64% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 0.8x | Better than 12% |
| Debt to assets | 31.5% | Better than 39% |
| Interest coverage | 1.7x | Better than 33% |
| Free cash flow / net income | 441.6% | Better than 92% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 78% |
| Upside to average target | 21.8% | Better than 48% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 88.51
- Open
- 88.43
- Day range
- 88.02 - 91.89
- Avg price
- 90.40
- Volume
- 19.63M
- Turnover
- 1.77B
- Turnover ratei
- 1.54%
- Volume ratioi
- 2.55
- Amplitudei
- 4.38%
- 52-week rangei
- 67.99 - 109.22
Valuation
- P/Ei
- 65.76
- P/E (TTM)i
- 24.12
- P/Bi
- 1.47
- EPSi
- 1.39
- Book value / shi
- 62.32
- Net profit
- 1.78B
- Net assets
- 79.70B
Share structure
- Market cap
- 116.91B
- Float capi
- 116.68B
- Shares out
- 1.28B
- Float sharesi
- 1.28B
Dividend & listing
- Div yield (TTM)i
- 2.91%
- Dividend (TTM)
- 2.66
- Listing date
- 1970-01-01
16.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-403.03M net over the window
Short interest
- Shares short
- 16.19M
- % of floati
- 1.27%
- Days to coveri
- 1.57
- As of
- 2026-10-15
Frequently asked questions
What is the current stock price of CVS Health (CVS)?
CVS Health last traded at 91.41. The quote on this page refreshes every few seconds while US markets are open.
What is CVS Health's market cap?
About 116.91B.
What is the P/E ratio of CVS Health?
The trailing twelve-month P/E is 24.12, below its own 5-year average of 32.35 — toward the top of its historical range (67.09% percentile). See the Valuation tab for the full history.
Does CVS Health pay a dividend?
Yes. The trailing dividend yield is 2.91%. The 2025 payout was little changed from 2024. See the Dividends tab for the full payment history.
Is CVS Health a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 114.59, which implies 25.4% upside from the current price. This is not investment advice.
What is CVS Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CVS Health a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-04 02:29:51 · For reference only, not investment advice and not tailored to your situation.
CVS Health discussion 0 comments